[Bestrabucil-induced complete remission in a case of follicular lymphoma, medium-sized cell type, stage IV (leukemic)].

Abstract

Bestrabucil, a chlorambucil-estradiol conjugate known to accumulate in malignant cells irrespective of the presence or absence of estrogen receptor, was administered to a 41-year-old man with follicular lymphoma, medium-sized cell type (LSG classification) stage IV (leukemic). A daily dose of 100 mg was given for two weeks and then 200 mg for a week. The WBC dropped from 43,100/mm3 with 82% abnormal lymphocytes to 12,800/mm3, and the drug was discontinued. It was resumed two weeks later at a daily dose of 50 mg. Four weeks thereafter, complete remission was obtained with the disappearance of all peripheral adenopathies and abnormal cells from the bone marrow. The patient remains disease-free for more than eight months on a maintenance dose of 50 mg per day. Transient erythema and gynecomastia have been the only side effects so far observed.

• Authors: M Hirano, S Shirakawa
• Journal: Gan no rinsho. Japan journal of cancer clinics (Gan No Rinsho) Vol. 32 Issue 11 Pg. 1491-4 (Sep 1986) ISSN: 0021-4949 [Print] Japan
• PMID: 3534347 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Chlorambucil
• Estradiol
• bestrabucil

Topics

• Adult
• Chlorambucil (analogs & derivatives, therapeutic use)
• Estradiol (analogs & derivatives, therapeutic use)
• Humans
• Lymph Nodes (pathology)
• Lymphoma, Follicular (drug therapy, pathology)
• Male
• Neoplasm Staging